Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Dennis E. Condon sold 9,000 shares of the firm’s stock in a transaction on Friday, September 10th. The shares were sold at an average price of $73.50, for a total transaction of $661,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of ESTA stock opened at $70.70 on Wednesday. The firm has a market cap of $1.68 billion, a P/E ratio of -76.85 and a beta of 1.06. The company has a debt-to-equity ratio of 0.74, a current ratio of 4.70 and a quick ratio of 3.82. Establishment Labs Holdings Inc. has a 1-year low of $16.50 and a 1-year high of $88.66. The firm has a fifty day moving average of $74.00 and a two-hundred day moving average of $72.41.
Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings data on Thursday, July 29th. The company reported ($0.22) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.06. The company had revenue of $31.99 million during the quarter, compared to analyst estimates of $31.50 million. Establishment Labs had a negative net margin of 19.78% and a negative return on equity of 29.92%. On average, sell-side analysts expect that Establishment Labs Holdings Inc. will post -1.14 EPS for the current year.
A number of research firms recently weighed in on ESTA. The Goldman Sachs Group raised their price target on shares of Establishment Labs from $68.00 to $78.00 and gave the company a “neutral” rating in a report on Tuesday, August 3rd. Zacks Investment Research raised shares of Establishment Labs from a “sell” rating to a “hold” rating in a report on Monday, September 6th. BTIG Research reaffirmed a “buy” rating and set a C$90.00 price target on shares of Establishment Labs in a report on Monday, August 23rd. Finally, Jefferies Financial Group began coverage on shares of Establishment Labs in a report on Friday, July 30th. They set a “buy” rating and a $90.00 price target for the company. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $84.60.
Establishment Labs Company Profile
Establishment Labs Holdings, Inc is a technology company, which engages in the design, development, manufacture, and marketing of silicone breast implants. It operates through the following geographical segments: Europe, Latin America, Asia Pacific and Middle East, and Other. The firm’s products include Motiva Implants, Motiva Flora Tissue Expander, Divina, and Puregraft.
Further Reading: Institutional Investors
Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.